Correlation Between Unicycive Therapeutics and Effector Therapeutics
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and Effector Therapeutics, you can compare the effects of market volatilities on Unicycive Therapeutics and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Effector Therapeutics.
Diversification Opportunities for Unicycive Therapeutics and Effector Therapeutics
-0.3 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Unicycive and Effector is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Effector Therapeutics go up and down completely randomly.
Pair Corralation between Unicycive Therapeutics and Effector Therapeutics
Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.02 times more return on investment than Effector Therapeutics. However, Unicycive Therapeutics is 1.02 times more volatile than Effector Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Effector Therapeutics is currently generating about -0.04 per unit of risk. If you would invest 73.00 in Unicycive Therapeutics on August 28, 2024 and sell it today you would lose (18.00) from holding Unicycive Therapeutics or give up 24.66% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 79.8% |
| Values | Daily Returns |
Unicycive Therapeutics vs. Effector Therapeutics
Performance |
| Timeline |
| Unicycive Therapeutics |
| Effector Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Unicycive Therapeutics and Effector Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Unicycive Therapeutics and Effector Therapeutics
The main advantage of trading using opposite Unicycive Therapeutics and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.| Unicycive Therapeutics vs. Transcode Therapeutics | Unicycive Therapeutics vs. Cardio Diagnostics Holdings |
| Effector Therapeutics vs. Indaptus Therapeutics | Effector Therapeutics vs. Jasper Therapeutics | Effector Therapeutics vs. RenovoRx | Effector Therapeutics vs. Ensysce Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |